Compare · ABBV vs AIMD
ABBV vs AIMD
Side-by-side comparison of AbbVie Inc. (ABBV) and Ainos Inc. (AIMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABBV and AIMD operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABBV is the larger of the two at $402.35B, about 24711.6x AIMD ($16.3M).
- Over the past year, ABBV is up 19.3% and AIMD is down 26.2% - ABBV leads by 45.4 points.
- AIMD has been more active in the news (12 items in the past 4 weeks vs 8 for ABBV).
- ABBV has more recent analyst coverage (25 ratings vs 0 for AIMD).
- Company
- AbbVie Inc.
- Ainos Inc.
- Price
- $227.67+1.37%
- $1.92-2.04%
- Market cap
- $402.35B
- $16.3M
- 1M return
- +9.19%
- +11.63%
- 1Y return
- +19.28%
- -26.15%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2012
- News (4w)
- 8
- 12
- Recent ratings
- 25
- 0
AbbVie Inc.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.
Latest ABBV
- Allergan Aesthetics Releases 'The Aesthetics Evolution: What Consumers Really Want' Highlighting Consumer Motivations and Expectations in Aesthetics
- AbbVie Presents New Data Across Its Blood Cancer Portfolio at EHA 2026
- AbbVie to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
- SEC Form SD filed by AbbVie Inc.
- AbbVie Announces European Commission Authorization of Expanded Label for VENCLYXTO® (venetoclax) to Include Additional Combinations in Previously Untreated Chronic Lymphocytic Leukemia
- FDA Approval for DECNUPAZ issued to ABBVIE INC
- U.S. FDA Approves DECNUPAZTM (pivekimab sunirine-pvzy) for Treatment of Adult Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare and Aggressive Blood Cancer With Limited Treatment Options
- SEC Form 144 filed by AbbVie Inc.
- AbbVie Announces Positive CHMP Opinion for MAVIRET® (glecaprevir/pibrentasvir) for the Treatment of Acute Hepatitis C Infection
- AbbVie Announces New Data at ASCO 2026 Demonstrating Breadth and Momentum Across its Next-Generation Oncology Pipeline
Latest AIMD
- Director Chiang Yao-Chung bought $7,175 worth of shares (3,500 units at $2.05) (SEC Form 4)
- Ainos Releases 2026 Mid-Year CEO Letter to Shareholders
- Director Chiang Yao-Chung bought $4,260 worth of shares (2,000 units at $2.13) (SEC Form 4)
- VASRO Research Highlights Ainos Smell AI Expansion into Emergency Department Operations
- Zacks SCR Discusses Ainos' Expansion of Smell AI into Healthcare Infrastructure Through NTUH Study
- Director Chiang Yao-Chung bought $575 worth of shares (250 units at $2.30) (SEC Form 4)
- Ainos Launches Smell AI Study at National Taiwan University Hospital for ER Overcrowding and Respiratory Infection Risk Analysis
- Director Chiang Yao-Chung bought $4,000 worth of shares (2,000 units at $2.00) (SEC Form 4)
- Director Lee Ting-Chuan sold $208,977 worth of shares (109,988 units at $1.90), decreasing direct ownership by 12% to 807,417 units (SEC Form 4) to satisfy tax liability
- Large owner Taiwan Carbon Nano Technology Corp sold $96,760 worth of shares (41,000 units at $2.36), decreasing direct ownership by 4% to 948,925 units (SEC Form 4) (withholding obligation)